DV3R Stock Chart & Stats
€13.96
-€0.19(-1.75%)
At close: 4:00 PM EDT
€13.96
-€0.19(-1.75%)
Day’s Range― - ―
52-Week Range€7.20 - €14.93
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
€492.41M
Enterprise Value€407.16
Total Cash (Recent Filing)€95.90M
Total Debt (Recent Filing)€2.46M
Price to Earnings (P/E)1498.2
Beta1.21
Next Earnings
Nov 10, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding34,698,795
10 Day Avg. Volume26
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)3.25
Price to Sales (P/S)4.24
P/FCF Ratio17.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.24Price Target Upside44.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.13
Revenue Forecast (FY)€92.25M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And Gross MarginsStrong revenue scale-up combined with exceptionally high gross margins indicates that Hepzato can generate substantial gross profit as treatment utilization expands. This creates room to support commercial investment, customer adoption and operating leverage, although profitability still needs to mature.
Positive Cash GenerationThe shift from deeply negative operating and free cash flow in 2021–2024 to sustained positive generation in 2025 and TTM is a meaningful fundamental improvement. Cash conversion can help fund commercial expansion and reduce reliance on external capital over the next several quarters.
Very Low Balance-sheet LeverageMinimal leverage gives Delcath considerable financial flexibility while it continues investing in its liver-directed therapy platform. A substantial equity base and limited debt burden reduce financing pressure, preserve capital-allocation options and improve resilience if operating results fluctuate.
Bears Say
Fragile ProfitabilityDespite strong gross margins, Delcath has not yet demonstrated durable operating leverage. Near-breakeven net profitability and a return to slightly negative operating profit suggest earnings remain sensitive to spending and product mix, raising execution risk as the business scales.
Revenue ConcentrationDependence on the U.S. market and a single core product makes results more sensitive to Hepzato adoption, treatment-center activation and eligible-patient volumes. Concentration can amplify the effect of execution setbacks and limits the diversification supporting more stable long-term growth.
Free Cash Flow VolatilityPositive free cash flow is encouraging, but its year-over-year decline shows that cash generation has not yet established a consistently upward pattern. Continued volatility could constrain the pace of internally funded investment and make future performance more dependent on operating execution.
Delcath Systems News
DV3R FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was €7.20 and its highest was €14.93 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is €492.41M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Nov 10, 2026 which is in 63 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Aug 06, 2026. The company reported €0.061 earnings per share for the quarter, beating the consensus estimate of -€0.077 by €0.138.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is -0.08.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 34,698,795 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of €0.061 in its last earnings report, beating expectations of -€0.077. Following the earnings report the stock price went down -0.139%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DE:DV3R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Delcath Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€20.24 (44.96% Upside)
€20.24 (44.96% Upside)
Blogger Sentiment
Bullish
DE:DV3R Sentiment 100%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Delcath Systems
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
DV3R Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced mix of positive commercial and clinical momentum (record new patient starts, robust volume growth, encouraging CHOPIN data driving adoption, solid revenue growth and strong cash balance) alongside meaningful near-term operational and financial headwinds (slower-than-expected site activations and trial enrollment, higher R&D and SG&A spend, a quarter-over-quarter decline in adjusted EBITDA and a small net loss, plus European reimbursement constraints and seasonality risks). Management remains optimistic about hitting at least $100M in revenue for 2026 and returning to positive adjusted EBITDA for the year, but several execution and enrollment risks temper the outlook.View all DE:DV3R earnings summariesDV3R Stock 12 Month Forecast
Average Price Target
€20.24
▲(44.96% Upside)
Technical Analysis
Penumbra
―
NovoCure
―
Sensus Healthcare
―
TransMedics Group
―
TriSalus Life Sciences
―